| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. | Director | Common Stock | 9,500 | $214,700 | $22.60 | 11 Sep 2025 | Direct |
| Rapport Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10,925 | 17 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | 11 Sep 2025 | 1 | +$79,100 | 4 | Director | 11 Sep 2025, 18:13 |
| RAPP | Rapport Therapeutics, Inc. | 17 Jun 2025 | 1 | $0 | 4 | Director | 18 Jun 2025, 16:15 |
| RAPP | Rapport Therapeutics, Inc. | 12 Mar 2025 | 1 | +$61,250 | 4 | Director | 13 Mar 2025, 17:00 |
| RAPP | Rapport Therapeutics, Inc. | 07 Nov 2024 | 1 | $0 | 4 | Director | 07 Nov 2024, 19:00 |
| RAPP | Rapport Therapeutics, Inc. | 07 Nov 2024 | 0 | $0 | 3 | Director | 07 Nov 2024, 18:27 |